Megan Korn

Megan Korn

Auto-generated profile, based on publicly available information

Megan Korn

Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York City, NY, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
GSGuangbin Shi
Guangbin Shi
CMClaire Miller
Claire Miller
SKSota Kuno
Sota Kuno
AHAlejandro G. Rey Hipolito
Alejandro G. Rey Hipolito
SNSalsabiel El Nagar
Salsabiel El Nagar
MPMichael E. Pacold
Michael E. Pacold
Decreased brain levels of coenzyme Q10 (CoQ10), an endogenously synthesized lipophilic antioxidant1,2, underpin encephalopathy in primary CoQ10 deficiencies3,4 and are associated with common neurodegenerative diseases and the ageing process5,6. CoQ10 supplementation does not increase CoQ10 pools in the brain or in other tissues. The recent discovery of the mammalian CoQ10 headgroup synthesis pathway, in which 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) makes 4-hydroxymandelate (4-HMA) to synthesize the CoQ10 headgroup precursor 4-hydroxybenzoate (4-HB)7, offers an opportunity to pharmacologically restore CoQ10 synthesis and mechanistically treat CoQ10 deficiencies. To test whether 4-HMA or 4-HB supplementation promotes CoQ10 headgroup synthesis in vivo, here we administered 4-HMA and 4-HB to Hpdl−/− mice, which model an ultra-rare, lethal mitochondrial encephalopathy in humans. Both 4-HMA and 4-HB were incorporated into CoQ9 and CoQ10 in the brains of Hpdl−/− mice. Oral treatment of Hpdl−/− pups with 4-HMA or 4-HB enabled 90–100% of Hpdl−/− mice to live to adulthood. Furthermore, 4-HB treatment stabilized and improved the neurological symptoms of a patient with progressive spasticity due to biallelic HPDL variants. Our work shows that 4-HMA and 4-HB can modify the course of mitochondrial encephalopathy driven by HPDL variants and demonstrates that CoQ10 headgroup intermediates can restore CoQ10 synthesis in vivo.

11 August 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
ANAshok Nuthanakanti
Ashok Nuthanakanti
MKMegan Korn
Megan Korn
RLRose Levenson-Palmer
Rose Levenson-Palmer
YWYue Wu
Yue Wu
NBNandhini Rajesh Babu
Nandhini Rajesh Babu
Alexander SerganovAlexander Serganov
Alexander Serganov

11 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VCVeronica Costiniti
Veronica Costiniti
MKMegan Korn
Megan Korn
WTWyatt Cameron Tran
Wyatt Cameron Tran
NBNandhini Rajesh Babu
Nandhini Rajesh Babu
ASAlbert Sohn
Albert Sohn
RBRobert S. Banh
Robert S. Banh
Neoantigen-based cancer immunotherapy is a promising approach that enables highly specific targeting of cancer cells through different biological tools and minimizing damage to healthy tissues. Despite this advantage, neoantigen therapies face significant challenges which can limit tumor immunogenicity, such as tumor heterogeneity, variable mutation rates, and immune evasion through loss or downregulation of antigen presentation. Pancreatic ductal adenocarcinoma (PDAC) is considered one of the most resistant tumors to immunotherapy in part due to its relatively low mutational burden, which results in poor neoantigen presentation and weak immune responses. However, several studies have demonstrated that PDAC patients with higher immunogenicity exhibit improved survival. In this work we show that systemic neoantigen production can be induced in PDAC and other cancers by leveraging the tumor microenvironment, specifically by tuning amino acid availability. By engineering new tools to monitor and target phenylalanine-to-tyrosine (FtY) substitutions in vitro and in vivo, we demonstrate that FtY mistranslational errors in PDAC can be modulated by altering the balance between phenylalanine (Phe) and tyrosine (Tyr). We demonstrated that FtY misincorporation reshapes the cancer cell proteome, generating new classes of targetable FtY neoantigens, including cell surface proteins (e.g. MHC) or immunopeptides. To induce FtY errors in PDAC tumors, mice were treated with nitisinone (an FDA approved HPD inhibitor) to increase Tyr levels. We found that Tyr elevation in vivo combined with immune checkpoint blockade (ICB), reduces tumor burden by enhanced T-cell cytotoxicity. Our findings reveal an anti-tumor therapeutic strategy that turns the translational error of FtY misincorporation into a targeted vulnerability.